# Steven E. Schild

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/steven-e-schild/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,998 |
| Field | Brain Metastases and Treatment |
| h-index | 87 |
| i10-index | 426 |
| Last Known Institution | Mayo Clinic Hospital |
| OpenAlex ID | https://openalex.org/A5062848479 |
| ORCID iD | https://orcid.org/0000-0002-2850-4126 |
| Works | 838 |

## Researcher papers

- [Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study](https://scholariq.org/papers/standard-dose-versus-high-dose-conformal-radiotherapy-with-concurrent-and/)
- [Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/non-small-cell-lung-cancer-version-3-2022-nccn-clinical-practice-guidelines-in/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-2-2021/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-1-2020/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-4-2016/)
- [Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/long-term-results-of-nrg-oncology-rtog-0617-standard-versus-high-dose/)
- [NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-2-2023/)
- [Non–Small Cell Lung Cancer, Version 6.2015](https://scholariq.org/papers/non-small-cell-lung-cancer-version-6-2015/)
- [Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis](https://scholariq.org/papers/malignant-melanoma-in-the-21st-century-part-1-epidemiology-risk-factors/)
- [Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis](https://scholariq.org/papers/malignant-melanoma-in-the-21st-century-part-1-epidemiology-risk-factors-2/)

## Researcher topics

- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)
- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Management of metastatic bone disease](https://scholariq.org/topics/management-of-metastatic-bone-disease/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Mayo Clinic Hospital](https://scholariq.org/institutions/mayo-clinic-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.